{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:53:44Z","timestamp":1759366424224,"version":"build-2065373602"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.revmed.2008.10.019","type":"journal-article","created":{"date-parts":[[2009,2,8]],"date-time":"2009-02-08T04:10:54Z","timestamp":1234066254000},"page":"322-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hyper\u00e9osinophilies et affections h\u00e9matologiques"],"prefix":"10.1016","volume":"30","author":[{"given":"J.-V.","family":"Malfuson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Fagot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Konopacki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mangouka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Souleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"de Revel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2008.10.019_bib1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/archinte.163.11.1371-a","article-title":"Eosinophilia and diseases: clinical revision of 1862\u00a0cases","volume":"163","author":"Lombardi","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.revmed.2008.10.019_bib2","first-page":"196","article-title":"Eosinophilia: a study of 100\u00a0hospitalized patients","volume":"18","author":"Sade","year":"2007","journal-title":"J Intern Med"},{"key":"10.1016\/j.revmed.2008.10.019_bib3","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1034\/j.1398-9995.2002.23479.x","article-title":"Incidence of peripheral blood eosinophilia and the threshold eosinophile count for indicating hypereosinophilia-associated diseases","volume":"57","author":"Kobayashi","year":"2002","journal-title":"J Allergy"},{"key":"10.1016\/j.revmed.2008.10.019_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2008.10.019_bib5","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM199805283382206","article-title":"Eosinophilia","volume":"338","author":"Rothenberg","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2008.10.019_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophile","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.revmed.2008.10.019_bib7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJM199402243300804","article-title":"Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome","volume":"330","author":"Cogan","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2008.10.019_bib8","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","article-title":"Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia","volume":"341","author":"Simon","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2008.10.019_bib9","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1365-2141.2000.02097.x","article-title":"Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome","volume":"109","author":"Roufosse","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2008.10.019_bib10","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1067\/mai.2002.127003","article-title":"High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome","volume":"110","author":"de Lavareille","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2008.10.019_bib11","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.leukres.2006.10.005","article-title":"\u2018Idiopathic\u2019 eosinophilia with an occult T-cell clone: prevalence and clinical course","volume":"31","author":"Vaklavas","year":"2007","journal-title":"Leuk Res"},{"year":"2001","series-title":"Chronic eosinophile leukaemia and the hypeosinophilic syndrome. WHO classification of tumours; pathology and genetics of tumours of hematopoietic and lymphoid tissues","author":"Bain","key":"10.1016\/j.revmed.2008.10.019_bib12"},{"key":"10.1016\/j.revmed.2008.10.019_bib13","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2008.10.019_bib14","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2008.10.019_bib15","first-page":"817","article-title":"A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia","volume":"91","author":"Bacher","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2008.10.019_bib16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","article-title":"FIP1L1\u2013PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature","volume":"30","author":"Pardanani","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.revmed.2008.10.019_bib17","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403313","article-title":"Clinical and molecular features of FIP1L1\u2013PDFGRA (+) chronic eosinophilic leukemias","volume":"18","author":"Vandenberghe","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2008.10.019_bib18","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.leu.2403722","article-title":"Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35\u00a0French patients with normal conventional cytogenetics","volume":"19","author":"Roche-Lestienne","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2008.10.019_bib19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2005.05863.x","article-title":"Multilineage involvement of the fusion gene in patients with FIP1L1\/PDGFRA-positive hypereosinophilic syndrome","volume":"132","author":"Robyn","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2008.10.019_bib20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.20088","article-title":"Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia and systemic mastocytosis","volume":"77","author":"Bain","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2008.10.019_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00062752-200701000-00008","article-title":"Diagnosis and treatment of hypereosinophilic syndromes","volume":"14","author":"Fletcher","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.revmed.2008.10.019_bib22","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/hmg\/11.12.1391","article-title":"The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA","volume":"11","author":"Baxter","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.revmed.2008.10.019_bib23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/sj.leu.2404154","article-title":"Identification of a novel imatinib responsive KIF5B\u2013PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia","volume":"20","author":"Score","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2008.10.019_bib24","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/gcc.20359","article-title":"Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2\u2013PDGFRA fusion gene","volume":"45","author":"Walz","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.revmed.2008.10.019_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2141.2007.06628.x","article-title":"Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia","volume":"138","author":"Curtis","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2008.10.019_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000046641","article-title":"Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta","volume":"107","author":"Steer","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1016\/j.revmed.2008.10.019_bib27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukaemia with t(5;12) chromosomal translocation","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.revmed.2008.10.019_bib28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2008.10.019_bib29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000046639","article-title":"The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1","volume":"107","author":"Macdonald","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1016\/j.revmed.2008.10.019_bib30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cancergencyto.2007.11.011","article-title":"8p11 myeloproliferative syndrome preceded by t(8;9)(p11;q33), CEP110\/FGFR1 fusion transcript: morphologic, molecular, and cytogenetic characterization of myeloid neoplasms associated with eosinophilia and FGFR1 abnormality","volume":"181","author":"Park","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.revmed.2008.10.019_bib31","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2008.10.019_bib32","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.3324\/haematol.11841","article-title":"Interferon alpha induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation","volume":"92","author":"Helbig","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2008.10.019_bib33","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood.V83.10.2759.2759","article-title":"The idiopathic hypereosinophilic syndrome","volume":"83","author":"Weller","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2008.10.019_bib34","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.revmed.2004.09.023","article-title":"Cardiac manifestations of idiopathic hypereosinophilic syndrome","volume":"26","author":"Harzy","year":"2005","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2008.10.019_bib35","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2169\/internalmedicine.39.350","article-title":"Measurement of serum concentrations of cardiac troponin\u00a0T in patients with hypereosinophilic syndrome: a sensitive noninvasive marker of cardiac disorder","volume":"39","author":"Sato","year":"2000","journal-title":"Intern Med"},{"key":"10.1016\/j.revmed.2008.10.019_bib36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1532-429X-10-21","article-title":"Time course of eosinophilic myocarditis visualized by CMR","volume":"10","author":"Deb","year":"2008","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.revmed.2008.10.019_bib37","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/j.ijcard.2007.01.019","article-title":"Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease","volume":"126","author":"Syed","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.revmed.2008.10.019_bib38","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2008.10.019_bib39","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.revmed.2008.10.019_bib40","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","article-title":"Congestive heart failure is a rare event in patients receiving imatinib therapy","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2008.10.019_bib41","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2003-07-2393","article-title":"Serum concentration of cardiac troponin\u00a0T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes","volume":"102","author":"Pitini","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2008.10.019_bib42","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1\u2013PDGFRA-positive chronic eosinophilic leukaemia","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2008.10.019_bib43","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1\u2013PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2008.10.019_bib44","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1182\/blood-2007-07-100164","article-title":"Relapse following discontinuation of imatinib mesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukaemia: implications for optimal dosing","volume":"110","author":"Klion","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2008.10.019_bib45","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2008.07033.x","article-title":"A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1\u2013PDGFRA-expressing patients","volume":"141","author":"Helbig","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2008.10.019_bib46","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(03)00108-9","article-title":"PKC412 overcomes resistance to imatinib in a murine model of FIP1L1\u2013PDGFRalpha-induced myeloproliferative disease","volume":"3","author":"Cools","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.revmed.2008.10.019_bib47","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","article-title":"Sorafenib is a potent inhibitor of FIP1L1\u2013PDGFRalpha and the imatinib-resistant FIP1L1\u2013PDGFRalpha T674I mutant","volume":"108","author":"Lierman","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2008.10.019_bib48","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1182\/blood-2006-01-0285","article-title":"The FIP1L1\u2013PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)","volume":"107","author":"von Bubnoff","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2008.10.019_bib49","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jaci.2006.02.042","article-title":"Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report","volume":"117","author":"Klion","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2008.10.019_bib50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-89-2-167","article-title":"Therapy of the hypereosinophilic syndrome","volume":"89","author":"Parrillo","year":"1978","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2008.10.019_bib51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000085560","article-title":"Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis","volume":"114","author":"Butterfield","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.revmed.2008.10.019_bib52","first-page":"243","article-title":"Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon-alpha. Apropos of 7\u00a0cases","volume":"144","author":"Coutant","year":"1993","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1016\/j.revmed.2008.10.019_bib53","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood.V96.13.4285","article-title":"Interferon-alpha prevents spontaneous apoptosis of clonal Th2\u00a0cells associated with chronic hypereosinophilia","volume":"96","author":"Schandene","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2008.10.019_bib54","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.iac.2007.07.002","article-title":"Lymphocytic variant hypereosinophilic syndromes","volume":"27","author":"Roufosse","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.revmed.2008.10.019_bib55","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1056\/NEJMoa031261","article-title":"Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis","volume":"349","author":"Plotz","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2008.10.019_bib56","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2008.10.019_bib57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaci.2003.10.049","article-title":"Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes","volume":"113","author":"Garrett","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2008.10.019_bib58","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2004.08.027","article-title":"Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700","volume":"114","author":"Kim","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2008.10.019_bib59","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866308008801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866308008801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:23:46Z","timestamp":1759335826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866308008801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0248866308008801"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2008.10.019","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyper\u00e9osinophilies et affections h\u00e9matologiques","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2008.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}